Detalhe da pesquisa
1.
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
AIDS Res Ther
; 21(1): 17, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38515183
2.
Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.
J Infect Dis
; 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38134313
3.
An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
AIDS Res Ther
; 20(1): 17, 2023 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36949442
4.
Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
BMC Infect Dis
; 19(1): 484, 2019 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31146698
5.
Automated identification of brain new lesions in multiple sclerosis using subtraction images.
J Magn Reson Imaging
; 39(6): 1543-9, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24987754
6.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Lancet HIV
; 11(3): e156-e166, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38417976
7.
Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups.
Open Forum Infect Dis
; 9(8): ofac304, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36046700
8.
Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials.
HIV Res Clin Pract
; 22(2): 46-54, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180785
9.
Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies.
HIV Res Clin Pract
; 23(1): 9-14, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34913844
10.
Impact of colour on the bioreceptivity of granite to the green alga Apatococcus lobatus: Laboratory and field testing.
Sci Total Environ
; 745: 141179, 2020 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32758748
11.
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
J Acquir Immune Defic Syndr
; 94(3): e9-e12, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37850985
12.
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.
Neurology
; 90(16): e1425-e1434, 2018 04 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29661905
13.
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Neurology
; 90(20): e1805-e1814, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695594
14.
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
J Neurol
; 264(2): 304-315, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27888416
15.
A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.
Schizophr Res
; 164(1-3): 136-42, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25728831
16.
Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Neurology
; 92(11): 543, 2019 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30858245
17.
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.
Neurology
; 82(7): 573-81, 2014 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-24453078
18.
Patterns of responding on a balloon analogue task reveal individual differences in overall risk-taking: choice between guaranteed and uncertain cash.
J Gen Psychol
; 141(3): 207-27, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24940812
19.
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
Curr Alzheimer Res
; 11(1): 47-58, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24359500
20.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Lancet Neurol
; 11(2): 131-9, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22226929